[改善梅奥内镜评分的价值用于评估活性性结肠炎的治疗疗效]
1Department of Gastroenterology, Yulin First Hospital, Yulin 719000, China.
概括
改善的梅奥内镜评分 (IMES) 有效评估活跃性结肠炎 (UC) 的治疗结果. 与现有方法相比,这种新的评分系统证明了缓解的优越预测价值.
科学领域:
- 胃肠病学 胃肠病学
- 临床医学 临床医学
- 炎症性肠道疾病研究研究
背景情况:
- 活跃性性结肠炎 (UC) 需要对治疗疗效进行准确的评估.
- 目前的内镜评分系统在预测治疗反应方面可能存在局限性.
研究的目的:
- 评估改善梅奥内镜评分 (IMES) 的有效性,以评估活跃UC患者的治疗结果.
- 将IMES的预测性能与已建立的评分系统进行比较.
主要方法:
- 从103名活跃UC患者 (2015-2020年) 的临床和内镜数据的回顾性分析.
- 用梅奥内镜评分 (MES) 和性结肠炎内镜严重程度指数 (UCEIS) 评估内镜严重程度.
- IMES是通过将MES与疾病范围的蒙特利尔分类结合而开发的.
主要成果:
- 年轻的患者,广泛的疾病 (E3),高内镜评分 (MES=3,UCEIS>4,IMES>4),以及先进的治疗与较低的缓解率有关.
- IMES ≤ 4 是临床和内镜缓解的一个独立风险因素.
- 与蒙特利尔分类,MES和UCEIS相比,IMES显示了缓解的优异预测值 (临床AUC=0.7793,内镜0.7095)
结论:
- 改善的梅奥内镜评分 (IMES) 在评估活性性结肠炎的治疗疗效方面具有显著价值.
- 与现有的内镜评估相比,IMES提供了更好的缓解预测准确度.
更多相关视频
09:42Murine Endoscopy for In Vivo Multimodal Imaging of Carcinogenesis and Assessment of Intestinal Wound Healing and Inflammation
Published on: August 26, 2014
18.7K
09:01Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
10.1K
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
175
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
175
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
157
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
157
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
560
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
560
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
356
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
356
01:29Inflammatory Bowel Disease IV: Pharmacological Management
154
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
154
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
219
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
219